-Mediated Error-Prone Removal of Mitomycin C Interstrand Cross-Links
Departments of Experimental Radiation Oncology,1 Molecular Genetics,3 Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030,4 Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 037552
Received 28 December 2001/ Returned for modification 4 February 2002/ Accepted 10 October 2002
| ABSTRACT |
|---|
|
|
|---|
encoded by the human POLH gene. From these observations, we propose the existence of a recombination-independent and mutagenic repair pathway for the removal of ICLs in mammalian cells. | INTRODUCTION |
|---|
|
|
|---|
In Escherichia coli and lower eukaryotes, the repair of ICLs is carried out primarily by a combination of the nucleotide excision repair (NER) and homologous recombination pathways. In a model proposed by Cole et al. (9, 10) based on genetic evidence, the NER mechanism introduces incisions flanking the site of the cross-link on the same strand. The resulting gap is then repaired by using a lesion-free homologous chromosome as a donor via the recA-dependent homologous recombination pathway. Subsequent biochemical analyses fully confirmed that the removal of ICLs in E. coli is mediated by both NER and homologous recombination (39, 44, 45). Similarly, with Saccharomyces cerevisiae, a group of RAD3 mutants (deficient in NER) and a group of RAD52 mutants (deficient in homologous recombination) are hypersensitive to the killing of bifunctional alkylating agents, suggesting that both pathways are essential for the repair of ICLs (21, 28, 30, 38). These observations also indicated the presence of a combination of NER and homologous-recombination mechanisms in ICL repair. More recently, direct evidence of psoralen ICL-induced homologous recombination in budding yeast has been demonstrated (16). While the combined NER-homologous-recombination mechanism appears to be the predominant error-free pathway for ICL repair in E. coli and yeast, homology-independent ICL repair has also been observed in both organisms. In E. coli, a moderate level of ICL repair takes place in recombination-deficient backgrounds and is likely mediated by a lesion bypass process in which the gapped intermediate created by the Uvr(A)BC excinuclease is resynthesized by DNA polymerase II (polB) (4, 5) independently of undamaged homologous sequences. In S. cerevisiae, the pso1 mutant exhibits profound sensitivity to psoralen cross-links. Identification of the gene responsible for such sensitivity revealed that the pso1/rev3 locus encodes the catalytic subunit of polymerase
, a lesion bypass DNA polymerase (7, 31, 34). A possible role for polymerase
may be the resynthesis of the gap after the initial uncoupling of the cross-link. Consistent with this notion, the pso1 mutant was found to be defective in ICL processing in stationary-phase yeast cells (28). More recently, mutagenic repair of DNA ICLs was also detected in repair-proficient yeast cells (16).
Several mammalian mutants defective in homologous recombination are highly sensitive to bifunctional alkylating agents, which indicates an essential role for recombination in the repair of ICLs in higher eukaryotes (22, 32, 36). In contrast, most mammalian NER mutant cell lines display only moderate sensitivity to the cross-linking agents, suggesting that the NER mechanism may have a limited participation in the removal of DNA ICLs (3, 19). However, since ERCC1 and ERCC4/XPF mutants exhibit profound hypersensitivity to cross-linking agents, it has been suggested that the endonuclease activity of ERCC1-XPF may provide unhooking activity at ICL-stalled replication forks (25). These findings also imply that a pathway other than NER may recognize and process ICLs into recombinogenic substrates. The observation that nitrogen mustard treatment generates double-strand breaks (DSBs) in mammalian cells provides a connection between ICL repair and homologous recombination (12). Interestingly, a recent study of ICL repair as a function of the cell cycle showed that the introduction of psoralen ICLs during late S or G2 phase of the cell cycle did not activate the G2-M checkpoint, suggesting that mammalian cells are able to tolerate the presence of unrepaired ICLs until they are encountered by the DNA replication machinery (2). This suggests that ICLs can be converted into replication-induced DSBs that are subject to homologous recombination. As is the case with E. coli and yeast, an error-prone repair pathway exists in mammalian cells and appears to be dependent on NER and a lesion bypass mechanism (47). These findings may explain the observation that bifunctional alkylating agents are more mutagenic than their monofunctional derivatives (50).
As a model lesion, photoreactive psoralen derivatives have been used in most studies of ICL repair. The formation of psoralen-induced ICLs leads to drastic distortion of the double helix (13), which may be detected by a variety of damage recognition complexes that sense the integrity of the helical structure. Conversely, ICLs induced by mitomycin C (MMC) result in minimum disruption of the helix structure and also have a distinct sequence preference (35, 48). In a previous study, psoralen-induced ICLs were used to demonstrate the recombination-independent repair (RIR) of cross-links in a reporter-based reactivation assay (47). Here, we present data showing that repair of ICLs formed with MMC is similar to that of the psoralen ICLs, which involves a lesion bypass process. We also present evidence that transcription-coupled repair (TCR) plays an important role in the removal of ICLs located in the actively transcribed region. These results further substantiate a model of combined NER and lesion bypass mechanisms for error-prone ICL removal.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
(PolH) expressed from the resulting construct carried the Xpress tag (DLYDDDDK) at the N terminus. The expression of PolH was verified by immunoblotting with a monoclonal antibody against the Xpress tag (Invitrogen). Cell lines and tissue culture conditions. Mammalian cell lines used in this study were purchased from either the American Type Culture Collection (Manassas, Va.) or the Human Genetics Mutant Cell Repository (Camden, N.J.) unless otherwise stated. Xeroderma pigmentosum (XP) fibroblast cell lines XP2OS (XPA), XP4PA (XPC), XP6BE (XPD), and XP30RO (XPV) and Cockayne syndrome (CS) fibroblast cell line CS3BE (CSA) were maintained in minimal essential medium (MEM) supplemented with 15% fetal calf serum (FCS). The human repair-proficient cell lines HT-1080 (fibrosarcoma) and RKO (colon cancer epithelial) and the Chinese hamster lung fibroblast cell line V79 were cultured in MEM supplemented with 10% FCS. The CHO AA8 cell line and its derived mutants UV24 (XPB), UV61 (ERCC6/CSB), UV24 (XPB), UV41 (XPF), and UV135 (XPG) were grown in Dulbecco MEM supplemented with 10% FCS. The E1KO7-5 (ERCC1KO) and E1KO-47 (ERCC1OK) CHO lines were maintained under similar conditions. The irs1 (XRCC2) and irs1SF (XRCC3) mutants were maintained in MEM supplemented with 10% FCS.
Repair reactivation assay. In order to introduce the cross-linked reporter substrates into cultured cells, transient transfections were performed with the FuGENE-6 reagent (Roche Molecular Biochemicals) according to the recommendations of the manufacturer. When needed, carrier DNA was used to equalize the total amount of plasmid DNA. For the luciferase reactivation assay, 0.1 to 2.5 ng of cross-linked or unmodified control substrate was used for transfections of 1.5 x 105 cells seeded in 35-mm-diameter plates. Cells were harvested for the preparation of protein extracts 30 h after transfection. In the experiments where TCR mutants were examined, cells were harvested 18 h after transfection. The luciferase activity was determined by using the Luciferase Assay System (Promega) and measured on a Moonlight 3010 luminometer (Pharmingen). The linear ranges of the luciferase assay, both in terms of the amount of transfected DNA and the amount of protein extract used in the luciferase assay, were established individually for each cell line. Each transfection was performed at least three times, and the standard deviation is provided for each data point.
Mutation analysis. MMC cross-linked plasmid (150 ng) was transfected into 5 x 105 cells/60-mm-diameter plate and harvested 30 h after transfection. Plasmid DNA was recovered by a modified alkaline lysis procedure (14) and subsequently electroporated into the E. coli AB2480 (uvrA recA) mutant (17), which is defective in both NER and homologous recombination. The resulting colonies were lysed and directly amplified by PCR to generate a 255-bp fragment flanking the cross-linked region. The PCR products were digested with BspDI to identify colonies containing plasmid that was resistant to BspDI cleavage. Plasmids that were found resistant to BspDI cleavage were further analyzed by DNA sequencing.
| RESULTS |
|---|
|
|
|---|
Repair of MMC ICL in NER-proficient cells. We prepared plasmid substrate containing a site-specific MMC cross-link by using in vitro ligation to insert the cross-linked oligonucleotide into the plasmid vector as described previously (26). The MMC cross-link was positioned between the CAP (transcription initiation) site of a cytomegalovirus promoter and the translation initiation site of the downstream firefly luciferase reporter gene. As shown (Fig. 1B), the purified cross-linked plasmid substrate contained no detectable amount of un-cross-linked plasmid or empty vector. As a result of the presence of the MMC ICLs, the transcription of the luciferase reporter gene becomes dependent upon the removal of the cross-links. To quantify the level of ICL repair, we constructed an identical reporter plasmid without cross-links. The efficiency of the ICL repair was determined by normalizing luciferase activities from cells transfected with cross-linked plasmid against those of cells transfected with an unmodified plasmid. Initially, two human repair-proficient cell lines (HT-1080 and RKO) were examined, and the reactivation of luciferase activity in these cell lines was found to range between 40 and 60% of that observed with unmodified plasmid (Fig. 2). These results suggest that a substantial portion of the MMC ICLs in the reporter plasmid were removed to allow the expression of the luciferase gene. Also, the repair of the cross-links apparently took place in the absence of undamaged homologous sequences, since there is no genomic sequence exhibiting significant homology to the pCMV-LUC plasmid according to the results of a BLAST search of the complete human sequence from the Celera database. Moreover, a sequence alignment analysis of the pCMV-LUC vector showed no tandem repeats flanking the cross-linked region to support a single-strand annealing type of intramolecular recombination that could lead to the reactivation of luciferase expression. To examine this RIR of ICLs in other repair-proficient cells, we tested two normal hamster cell lines, AA8 and V79. Both cell lines generated levels of reactivation similar to those of the human repair-proficient cells (Fig. 2).
|
|
Lesion bypass PolH plays a role in the repair of MMC ICLs.
In yeast, loss of the translesion polymerase
leads to severe sensitivity to cross-linking agents (31, 34). In mammals, XPV mutant cells exhibited a high mutation frequency and altered mutation spectrum when triplex-forming oligonucleotide-directed psoralen adducts were introduced (37). In light of these observations, we tested an XP-variant mutant cell line, XP30RO, which is defective in the human lesion bypass PolH (23, 27). The result (Fig. 4A) showed a drastic reduction in the reactivation of the luciferase reporter, suggesting an important role for the POLH gene product in the RIR of MMC ICLs.
|
Lack of XRCC2 and XRCC3 functions does not affect RIR of ICLs. The pivotal role of recombinational ICL repair mechanisms is reflected by the extreme hypersensitivity of the irs1 and irs1SF mutants to cross-linking agents (6). The mechanistic basis for the cross-link hypersensitivity has been identified as a defect in gene conversion (22, 36). We tested both the irs1 and the irs1SF mutant to see whether the loss of recombinational ICL repair function influences reactivation in our assay system. Our results (Fig. 3B) showed that the repair of the MMC ICLs was normal in both the irs1 and the irs1SF mutant compared to that in their isogenic parental cell lines V79 and AA8, respectively. These observations provide additional evidence that the repair of MMC ICLs occurs in the absence of homologous recombination.
Involvement of transcription-coupled NER in the RIR of MMC ICLs. The site-specific MMC ICL was placed in an actively transcribed region in the luciferase reporter plasmid. Therefore, TCR may play a role in the recombination-independent removal of cross-links. We tested two cell lines, CS3BE and UV61, that are deficient in the TCR genes CSA and CSB, respectively. Based on the kinetics of TCR, the cells were harvested 18 h after transfection for the luciferase assay instead of 30 h after transfection as in the experiment described above. By shortening the incubation time, the involvement of TCR, if any, would not be masked by the global repair pathway, as may occur when longer incubation times are allowed. As shown (Fig. 5), both mutants have substantially reduced levels of ICL repair compared to that of repair-proficient cells, albeit the reduction is not to the same extent as that in XPA and ERCC1 mutants. Complementing the CS3BE mutant with wild-type CSA cDNA through transient transfection resulted in the substantial restoration of ICL repair. Similar results were obtained when the above-mentioned cell lines were tested with psoralen-cross-linked luciferase reporter plasmid (data not shown). These results, taken together, suggest that the TCR pathway plays a significant role in the repair of the MMC ICLs in the cross-linked luciferase reporter substrate.
|
|
We also studied mutation induction in the cross-linked pCMV-LUC plasmid recovered from XPV cells. Analysis of 75 recovered colonies produced 11 independent clones with mutations around the cross-linked site. The resulting mutation frequency (15%) may indicate a reduction in the mutation rate compared to the 22% mutation rate (21 out of 96) for repair-proficient HT-1080 and AA8 cells. The positions and nature of base substitutions, primarily A for C and T for C, are similar to those of XPV-positive repair-proficient cells. These results suggest that PolH contributes to the ICL-induced mutation but that other lesion bypass polymerases may have redundant roles in the RIR mechanism to remove MMC ICLs.
| DISCUSSION |
|---|
|
|
|---|
Model for the RIR of ICLs.
The incision step of the NER pathway consists of a number of essential activities: the excinuclease activities of ERCC1-XPF and XPG, the helicase activity of TFIIH (XPB and XPD), and the damage-binding activities of XPA and XPC-human RAD23B. We found that all five factors were required for the RIR of the MMC ICLs, a result that is consistent with the results of previous studies of photoactivated psoralen-mediated ICLs (47). A number of in vitro studies have suggested the involvement of NER incision activities in ICL processing. We have shown that the ERCC1-XPF complex is essential in ICL-induced repair synthesis (26). Dual incisions 5' to the cross-link were observed and postulated to result in a futile cycle of DNA synthesis (33). Also, the ERCC1-XPF heterodimer was shown to exhibit an endonuclease activity capable of introducing incisions on the unpaired 3' tail of the cross-link placed in a duplex 4 to 6 bases from a junction with unpaired DNA (25). These incision reactions, however, do not lead to the uncoupling of the ICLs, which is a crucial step in ICL removal. Conversely, if the NER dual incisions flanked the cross-linked base on the same strand, the resulting gap structure would effectively provide an uncoupling mechanism. The observed participation of Pol
in the experiments in our study can be best explained by a lesion bypass gap-filling process, which is substantiated by the identification of mutations at the site opposing the cross-linked base. These data, collectively, support a model proposed in Fig. 7. Moreover, ICLs formed with psoralen and MMC differ drastically in their degrees of helix distortion and their ICL configurations and have distinct base preferences (13, 35, 48). Hence, the RIR model may apply to ICLs in general.
|
TCR is evidently a major contributor in the RIR of MMC ICLs. Our results with the XP4PA mutant, however, showed that the repair of the MMC ICLs was also affected in an XPC-deficient cell line. Additional studies may be required to understand why the loss of XPC also affects ICL repair in the XPC mutants, which presumably have an intact TCR function.
Recombination-independent ICL repair is likely a minor pathway in mammalian cells. Two types of DNA lesions, DSBs and ICLs, affect both strands of the double helix and can be repaired through either error-free mechanisms that involve homologous recombination with undamaged homologous sequences as donors or error-prone mechanisms. In the case of radiation-induced DSBs, the nonhomologous-end-joining pathway appears to be the predominant mechanism in mammals, as demonstrated by the severe radiation sensitivity of Ku mutants, while mutants such as XRCC2 and XRCC3 that are defective in the gene conversion mechanism exhibit minor sensitivities to ionizing radiation (11). These same XRCC mutants are, nevertheless, extremely sensitive to ICL-inducing agents, indicating that homologous recombination is likely part of the major pathway for ICL repair. In mammals, the loss of NER function results in moderate sensitivity to cross-linking agents (3, 19). Thus, the NER lesion bypass mechanism does not seem to be the predominant pathway for ICL removal from chromosomal DNA in mammalian cells, despite the relatively high efficiency of ICL repair in our plasmid reporter constructs.
A number of factors may limit the participation of the RIR mechanism. At the site of an ICL, strand separation is severely restricted by the cross-link, which consequently inhibits the formation of the bubble structure required for the dual NER incisions. As a result, the efficiency and accuracy of introducing flanking incisions may be limited. In budding yeast, the RIR of psoralen ICLs has recently been characterized (16) and a rev3/polymerase
-dependent repair of nitrogen mustard-mediated ICLs has been shown to function mostly in stationary-phase yeast cells (28). Similarly, in mammalian cells, specific stages of the cell cycle in which ICLs are encountered may further limit the role of the RIR pathway (15). Although the mechanism for the RIR of ICLs may not contribute extensively to the overall removal of ICLs genome-wide, its error-prone nature may be an important source of induced mutagenesis by cross-linking agents.
| ACKNOWLEDGMENTS |
|---|
This work was supported by National Cancer Institute grants CA75160 (R.J.L.), CA76172 (L.L.), and CA91029 (L.L.).
H. Zheng and X. Wang contributed equally to this work.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Akkari, Y. M. N., R. L. Bateman, C. A. Reifsteck, S. B. Olson, and M. Grompe. 2000. DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol. Cell. Biol. 20:8283-8289.
3. Andersson, B. S., T. Sadeghi, M. J. Sicilano, R. J. Legerski, and D. Murray. 1996. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosamide analogs. Cancer Chemother. Pharmacol. 38:406-416.[CrossRef][Medline]
4. Berardini, M., P. L. Foster, and E. L. Loechler. 1999. DNA polymerase II (polB) is involved in a new DNA repair pathway for DNA interstrand cross-links in Escherichia coli. J. Bacteriol. 181:2878-2882.
5. Berardini, M., W. Mackay, and E. L. Loechler. 1997. Evidence for a recombination-independent pathway for the repair of DNA interstrand cross-links based on a site-specific study with nitrogen mustard. Biochemistry 36:3506-3513.[CrossRef][Medline]
6. Caldecott, K., and P. Jeggo. 1991. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat. Res. 255:111-121.[CrossRef][Medline]
7. Cassier-Chauvat, C., and E. Moustacchi. 1988. Allelism between pso1-1 and rev3-1 mutants and between pso2-1 and snm1 mutants in Saccharomyces cerevisiae. Curr. Genet. 13:37-40.[CrossRef][Medline]
8. Christians, F. C., and P. C. Hanawalt. 1992. Inhibition of transcription and strand-specific DNA repair by alpha-amanitin in Chinese hamster ovary cells. Mutat. Res. 274:93-101.[CrossRef][Medline]
9. Cole, R., S. D. Levitan, and R. R. Sinden. 1976. Removal of psoralen interstrand crosslinks from DNA of Escherichia coli: mechanism and genetic control. J. Mol. Biol. 103:39-59.[CrossRef][Medline]
10. Cole, R. S. 1973. Repair of DNA containing interstrand crosslinks in Escherichia coli: sequential excision and recombination. Proc. Natl. Acad. Sci. USA 70:1064-1068.
11. Collins, A. R. 1993. Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics. Mutat. Res. 293:99-118.[CrossRef][Medline]
12. De Silva, I. U., P. J. McHugh, P. H. Clingen, and J. A. Hartley. 2000. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 20:7980-7990.
13. Eichman, B. F., B. H. Mooers, M. Alberti, J. E. Hearst, and P. S. Ho. 2001. The crystal structures of psoralen cross-linked DNAs: drug-dependent formation of Holliday junctions. J. Mol. Biol. 308:15-26.[CrossRef][Medline]
14. Faruqi, A. F., M. M. Seidman, D. J. Segal, D. Carroll, and P. M. Glazer. 1996. Recombination induced by triple-helix-targeted DNA damage in mammalian cells. Mol. Cell. Biol. 16:6820-6828.[Abstract]
15. Fujiwara, Y. 1982. Defective repair of mitomycin C crosslinks in Fanconi's anemia and loss in confluent normal human and xeroderma pigmentosum cells. Biochim. Biophys. Acta 699:217-225.[Medline]
16. Greenberg, R. B., M. Alberti, J. E. Hearst, M. A. Chua, and W. A. Saffran. 2001. Recombinational and mutagenic repair of psoralen interstrand cross-links in Saccharomyces cerevisiae. J. Biol. Chem. 276:31551-31560.
17. Gurzadyan, G. G., H. Gorner, and D. Schulte-Frohlinde. 1995. Ultraviolet (193, 216 and 254 nm) photoinactivation of Escherichia coli strains with different repair deficiencies. Radiat. Res. 141:244-251.[Medline]
18. Henning, K. A., L. Li, N. Iyer, L. D. McDaniel, M. S. Reagan, R. Legerski, R. A. Schultz, M. Stefanini, A. R. Lehmann, and L. V. Mayne. 1995. The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 82:555-564.[CrossRef][Medline]
19. Hoy, C. A., L. H. Thompson, C. L. Mooney, and E. P. Salazar. 1985. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res. 45:1737-1743.
20. Islas, A. L., F. J. Baker, and P. C. Hanawalt. 1994. Transcription-coupled repair of psoralen cross-links but not monoadducts in Chinese hamster ovary cells. Biochemistry 33:10794-10799.[CrossRef][Medline]
21. Jachymczyk, W. J., R. C. Von Borstel, M. R. A. Mowat, and P. J. Hastings. 1981. Repair of interstrand cross-links in DNA of Saccharomyces cerevisiae requires two systems of DNA repair: the RAD3 system and the RAD51 system. Mol. Gen. Genet. 182:196-205.[CrossRef][Medline]
22. Johnson, R. D., N. Liu, and M. Jasin. 1999. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature 401:397-399.[CrossRef][Medline]
23. Johnson, R. E., C. M. Kondratick, S. Prakash, and L. Prakash. 1999. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 285:263-265.
24. Jones, C. J., and R. D. Wood. 1993. Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA. Biochemistry 32:12096-12104.[CrossRef][Medline]
25. Kuraoka, I., W. R. Kobertz, R. R. Ariza, M. Biggerstaff, J. M. Essigmann, and R. D. Wood. 2000. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J. Biol. Chem. 275:26632-26636.
26. Li, L., C. A. Peterson, X. Lu, P. Wei, and R. J. Legerski. 1999. Interstrand cross-links induce DNA synthesis in damaged and undamaged plasmids in mammalian cell extracts. Mol. Cell. Biol. 19:5619-5630.
27. Masutani, C., R. Kusumoto, A. Yamada, N. Dohmae, M. Yokoi, M. Yuasa, M. Araki, S. Iwai, K. Takio, and F. Hanaoka. 1999. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 399:700-704.[CrossRef][Medline]
28. McHugh, P. J., W. R. Sones, and J. A. Hartley. 2000. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol. Cell. Biol. 20:3425-3433.
29. Mellon, I., G. Spivak, and P. C. Hanawalt. 1987. Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 51:241-249.[CrossRef][Medline]
30. Miller, R. D., L. Prakash, and S. Prakash. 1982. Genetic control of excision of Saccharomyces cerevisiae interstrand DNA cross-links induced by psoralen plus near-UV light. Mol. Cell. Biol. 2:939-948.
31. Morrison, A., R. B. Christensen, J. Alley, A. K. Beck, E. G. Bernstine, J. F. Lemontt, and C. W. Lawrence. 1989. REV3, a Saccharomyces cerevisiae gene whose function is required for induced mutagenesis, is predicted to encode a nonessential DNA polymerase. J. Bacteriol. 171:5659-5667.
32. Moynahan, M. E., T. Y. Cui, and M. Jasin. 2001. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61:4842-4850.
33. Mu, D., T. Bessho, L. V. Nechev, D. J. Chen, T. M. Harris, J. E. Hearst, and A. Sancar. 2000. DNA interstrand cross-links induce futile repair synthesis in mammalian cell extracts. Mol. Cell. Biol. 20:2446-2454.
34. Nelson, J. R., D. W. Lawrence, and D. C. Hinkle. 1996. Thymine-thymine dimer bypass by yeast DNA polymerase zeta. Science 272:1646-1649.[Abstract]
35. Norman, D., D. Live, M. Sastry, R. Lipman, B. E. Hingerty, M. Tomasz, S. Broyde, and D. J. Patel. 1990. NMR and computational characterization of mitomycin cross-linked to adjacent deoxyguanosines in the minor groove of the d(T-A-C-G-T-A)·d(T-A-C-G-T-A) duplex. Biochemistry 29:2861-2875.[CrossRef][Medline]
36. Pierce, A. J., R. D. Johnson, L. H. Thompson, and M. Jasin. 1999. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13:2633-2638.
37. Raha, M., G. Wang, M. M. Seidman, and P. M. Glazer. 1996. Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant. Proc. Natl. Acad. Sci. USA 93:2941-2946.
38. Simon, J. A., P. Szankasi, D. K. Nguyen, C. Ludlow, H. M. Dunstan, C. J. Roberts, E. L. Jensen, L. H. Hartwell, and S. H. Friend. 2000. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60:328-333.
39. Sladek, F. M., M. M. Munn, W. D. Rupp, and P. Howard-Flanders. 1989. In vitro repair of psoralen-DNA cross-links by RecA, UvrABC, and the 5'-exonuclease of DNA polymerase I. J. Biol. Chem. 264:6755-6765.
40. Sugasawa, K., J. M. Ng, C. Masutani, S. Iwai, P. J. van der Spek, A. P. Eker, F. Hanaoka, D. Bootsma, and J. H. Hoeijmakers. 1998. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol. Cell 2:223-232.[CrossRef][Medline]
41. Theicher, B. A. 1997. Antitumor alkylating agents, p. 405-414. In V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (ed.), Cancer: principles and practice of oncology, 5th ed. Lippincott-Raven, Philadelphia, Pa.
42. Tomasz, M. 1994. DNA adducts of the mitomycins, p. 349-357. In K. Hemminki, A. Dipple, D. E. G. Shuker, D. Segerback, F. F. Kadlubar, and H. Bartsch (ed.), DNA adducts: identification and biological significance, 1st ed. IARC, Lyon, France.D. A. K.D. A.
43. Troelstra, C., A. van Gool, J. de Wit, W. Vermeulen, D. Bootsma, and J. H. Hoeijmakers. 1992. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 71:939-953.[CrossRef][Medline]
44. Van Houten, B., H. Gamper, J. E. Hearst, and A. Sancar. 1986. Construction of DNA substrates modified with psoralen at a unique site and study of the action mechanism of ABC excinuclease on these uniformly modified substrates. J. Biol. Chem. 261:14135-14141.
45. Van Houten, B., H. Gamper, S. R. Holbrook, J. E. Hearst, and A. Sancar. 1986. Action mechanism of ABC excision nuclease on a DNA substrate containing a psoralen crosslink at a defined position. Proc. Natl. Acad. Sci. USA 83:8077-8081.
46. Volker, M., M. J. Mone, P. Karmakar, A. van Hoffen, W. Schul, W. Vermeulen, J. H. Hoeijmakers, R. van Driel, A. A. van Zeeland, and L. H. Mullenders. 2001. Sequential assembly of the nucleotide excision repair factors in vivo. Mol. Cell 8:213-224.[CrossRef][Medline]
47. Wang, X., C. A. Peterson, H. Zheng, R. S. Nairn, R. J. Legerski, and L. Li. 2001. Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol. Cell. Biol. 21:713-720.
48. Warren, A. J., and J. W. Hamilton. 1996. Synthesis and structural characterization of the N2G-mitomycin C-N2G interstrand cross-link in a model synthetic 23 base pair oligonucleotide DNA duplex. Chem. Res. Toxicol. 9:1063-1071.[CrossRef][Medline]
49. Warren, A. J., A. E. Maccubbin, and J. W. Hamilton. 1998. Detection of mitomycin C-DNA adducts in vivo by 32P-postlabeling: time course for formation and removal of adducts and biochemical modulation. Cancer Res. 58:453-461.
50. Wijen, J. P., M. J. Nivard, and E. W. Vogel. 2000. The in vivo genetic activity profile of the monofunctional nitrogen mustard 2-chloroethylamine differs drastically from its bifunctional counterpart mechlorethamine. Carcinogenesis 21:1859-1867.
51. Zhang, Y., F. Yuan, X. Wu, O. Rechkoblit, J. S. Taylor, N. E. Geacintov, and Z. Wang. 2000. Error-prone lesion bypass by human DNA polymerase eta. Nucleic Acids Res. 28:4717-4724.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|